Anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months.

reversibly inhibits hypoxia-inducible factor prolyl hydroxylase-1 (PH1), PH2, and PH3, which stimulates transcription of the erythropoietin gene in the kidneys and liver, leading to increased levels of endogenous erythropoietin.

1. Protein binding: ?99.5%. 2. Metabolism: Hepatic primarily via glucuronidation by UDP-glucuronosyltransferase (UGT) enzymes. 3. Half-life elimination: 9.2 hours (in patients on chronic hemodialysis). 4. Time to peak: ~2 to 3 hours. 5. Excretion: Urine: 58.9% (<1% as unchanged drug); feces: 26.9% (9% as unchanged drug).

uncontrolled hypertension

Vafseo should only be used during pregnancy if the benefit justifies the potential risk to the fetus.

Breastfeeding not recommended until two days after the final dose.

Hypertension, Diarrhea, thrombosis, nausea

Doses may range from 150 mg to a maximum of 600 mg.

It is not known if VAFSEO is safe and effective in children.

Not indicated for use in patients with chronic kidney disease not receiving dialysis.

Not recommended in patients with cirrhosis or active, acute liver disease.

Store at 20°C to 25°C, do not repackage.